← Eichor
Study identifier: NCT06660420 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)

Condition: Phase 1 · Recurrent Melanoma · Refractory Melanoma  ·  Sponsor: M.D. Anderson Cancer Center

PhasePhase 1
Planned participants39
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

To find the highest tolerable dose and recommended dose of PRAME-TCR-NK cells that can be given to participants with recurrent and/or refractory melanoma. The safety and tolerability of PRAME-TCR-NK cells will also be studied.

This description comes directly from the study's public registry record.

Talk to the study team

Isabella C Glitza Oliva, MD  ·  713-792-2921  ·  ICGlitza@mdanderson.org

Always discuss trial participation with your own doctor first.

Locations (1)

MD Anderson Cancer CenterHouston, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06660420